疫情期儿童疫苗接种下降是否应改变老年人肺炎球菌接种建议:成本效果分析
研究用马尔可夫模型评估COVID-19疫情下儿童PCV13接种下降对儿童和成人肺炎球菌疾病的影响,并分析其对≥65岁非免疫缺陷成人PCV13接种成本效果的影响。结果显示,儿童PCV13接种绝对下降10-50%持续1年可使老年肺炎球菌疾病增加4-19%,持续2年增加8-38%;仅在老年肺炎球菌疾病增幅>53%(对应儿童PCV13接种绝对下降>50%持续2年)时,才在每质量调整生命年20万美元阈值下支持老年PCV13接种。结论认为,疫情相关儿童PCV13接种下降需既大幅又持久,才能使老年PCV13接种更具经济性。
要点
- 儿童PCV13接种绝对下降10-50%持续1年,老年肺炎球菌疾病增加4-19%。
- 儿童PCV13接种下降持续2年,老年肺炎球菌疾病增加8-38%。
- 仅当老年肺炎球菌疾病增幅>53%时,PCV13接种在20万美元/QALY阈值下具成本效果。
核心结论
- COVID-19相关儿童PCV13接种下降需既大幅又持久,才能使非免疫缺陷老年人加强PCV13接种在经济上更有利。
研究设计与样本
- 采用马尔可夫模型估计<5岁儿童PCV13接种绝对下降10-50%、持续1-2年导致的儿童疾病负担。
- 将儿童模型输出整合入第二个马尔可夫模型,分析65岁人群肺炎球菌接种策略的成本效果。
主要发现
- 儿童PCV13接种绝对下降10-50%持续1年,老年肺炎球菌疾病增加4-19%;持续2年增加8-38%。
- 老年肺炎球菌疾病增幅需>53%才在每QALY 20万美元阈值下支持PCV13接种,对应儿童PCV13接种绝对下降>50%持续2年。
关键数值与推荐
- 成本效果阈值:每质量调整生命年(QALY)20万美元。
- 老年肺炎球菌疾病增幅>53%时,PCV13接种在非免疫缺陷老年人中具成本效果。
临床怎么用
- 当前疫情下儿童PCV13接种下降幅度和持续时间若未达上述阈值,维持或加强老年PCV13接种的经济性可能有限。
局限性
- 模型假设儿童接种下降导致儿童和老年PCV13血清型肺炎球菌疾病成比例增加,且无补接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic is causing declines in childhood immunization rates. We examined potential COVID-19-related changes in pediatric 13-valent pneumococcal conjugate vaccine (PCV13) use, subsequent impact on childhood and adult pneumococcal disease rates, and how those changes might affect the favorability of PCV13 use in non-immunocompromised adults aged ≥65 years. METHODS: A Markov model estimated pediatric disease resulting from decreased PCV13 use in children aged <5 years; absolute decreases from 10 to 50% for 1-2 years duration were examined, assuming no catch-up vaccination and that decreased vaccination led to proportionate increases in PCV13 serotype pneumococcal disease in children and seniors. Integrating pediatric model output into a second Markov model examining 65-year-olds, we estimated the cost effectiveness of older adult pneumococcal vaccination strategies while accounting for potential epidemiologic changes from decreased pediatric vaccination. RESULTS: One year of 10-50% absolute decreases in PCV13 use in <5-year-olds increased pneumococcal disease by an estimated 4-19% in seniors; 2 years of decreased use increased senior rates by 8-38%. In seniors, a >53% increase in pneumococcal disease was required to favor PCV13 use in non-immunocompromised seniors at a $200,000 per quality-adjusted life-year gained threshold, which corresponded to absolute decreases in pediatric PCV13 vaccination of >50% over a 2-year period. In sensitivity analyses, senior PCV13 vaccination was unfavorable if absolute decreases in pediatric PCV13 receipt were within plausible ranges, despite model assumptions favoring PCV13 use in seniors. CONCLUSION: COVID-19-related decreases in pediatric PCV13 use would need to be both substantial and prolonged to make heightened PCV13 use in non-immunocompromised seniors economically favorable.
引用
- Smith KJ, Wateska AR, Nowalk MP, et al. Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis. Vaccine. 2021. PMID: 34167834. doi:10.1016/j.vaccine.2021.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。